COMPREHENSIVE MYELOID PANEL BY NGS

NEXT GENERATION SEQUENCING BASED TESTING FOR MYELOID MALIGNANCIES

MUTATION TESTED: Comprehensive myeloid research panel for diagnosis of myeloid malignancies.

INDICATIONS FOR ORDERING: Involves genes implicated in acute myeloid leukemia, myeloproliferative neoplasms, myelodysplastic syndrome, MDS/MPN, pediatric myeloid malignancies. This is important for diagnosis, and risk stratification in these cases.

METHOD USED: Next Generation Sequencing (NGS)

SPECIMENS – Type, storage and transport

• Type: Non-diluted peripheral blood sample/bone marrow aspirate in an EDTA (lavender) tube..PLEASE AVOID HEPARINATED BLOOD

Bone Marrow: Min. 5mL

Whole Blood: 5 mL

• Transport: Specimens must be received within 24 hours of collection maintained at 40C
• Storage: Whole Blood or Bone Marrow. Separate specimens must be submitted when multiple tests are ordered.
• Extracted DNA: Separate specimens must be submitted when multiple tests are ordered.
• Unacceptable samples: Specimens collected in anticoagulants other than EDTA, haemolysed/clotted samples

TEST DESCRIPTION: This is a next generation sequencing based assay to detect mutations in the myeloid malignancy genes enlisted above. This assay is done using amplicon based sequencing on the Ion Torrent (LifeTechnologies, USA) PGM and/or S5 platform, with a gene panel prepared and provided by ThermoFischer Scientific (LifeTechnologies, USA)

TURNAROUND TIME: 15 (fifteen) working days from receipt of sample

QUALITY ASSURANCE & COMPETENCY TESTING: Regular internal quality checks and intra-lab comparisons are performed to ensure accurate and precise results. Material Safety Data Sheets (MSDS) may be ordered upon request. Highly trained personnel performing this test undergo regular competency assessments and attend regular conferences and educational programs in order to stay upbeat with the newer advances in the biology and diagnostics of the disease in question.

ACCREDITATION: NOT IN NABL SCOPE